A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Status:
Completed
Trial end date:
2016-07-18
Target enrollment:
Participant gender:
Summary
This research study is being done to measure the clinical benefit associated with
cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs
(organs other than bone or lymph nodes) and no longer responds to initial hormonal
(castration) therapy. This type of prostate cancer is called metastatic, castrate-resistant
prostate cancer.